Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

BINEX

KOSDAQ:A053030
Snowflake Description

Flawless balance sheet with proven track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
A053030
KOSDAQ
₩331B
Market Cap
  1. Home
  2. KR
  3. Pharmaceuticals & Biotech
Company description

BINEX Co., Ltd. operates as a pharmaceutical company in South Korea. The last earnings update was 22 days ago. More info.


Add to Portfolio Compare Print
  • BINEX has significant price volatility in the past 3 months.
A053030 Share Price and Events
7 Day Returns
5.5%
KOSDAQ:A053030
8.1%
KR Pharmaceuticals
1.9%
KR Market
1 Year Returns
-7%
KOSDAQ:A053030
-20.5%
KR Pharmaceuticals
-21.8%
KR Market
A053030 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
BINEX (A053030) 5.5% 29.9% 34% -7% -24.3% -32.9%
KR Pharmaceuticals 8.1% 7.4% -2.9% -20.5% -3.4% 18.9%
KR Market 1.9% -14.7% -19.6% -21.8% -19.8% -22%
1 Year Return vs Industry and Market
  • A053030 outperformed the Pharmaceuticals industry which returned -20.5% over the past year.
  • A053030 outperformed the Market in Korea (Republic of) which returned -21.8% over the past year.
Price Volatility
A053030
Industry
5yr Volatility vs Market
Related Companies

A053030 Value

 Is BINEX undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of BINEX to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for BINEX.

KOSDAQ:A053030 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.4%
Perpetual Growth Rate 10-Year KR Government Bond Rate 3.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for KOSDAQ:A053030
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year KR Govt Bond Rate 3.4%
Equity Risk Premium S&P Global 6.1%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.69
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.686 (1 + (1- 30%) (7.07%))
0.812
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.81
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 3.43% + (0.812 * 6.07%)
8.36%

Discounted Cash Flow Calculation for KOSDAQ:A053030 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for BINEX is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

KOSDAQ:A053030 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (KRW, Millions) Source Present Value
Discounted (@ 8.36%)
2020 13,600.00 Analyst x1 12,550.70
2021 16,564.38 Est @ 21.8% 14,106.96
2022 19,262.19 Est @ 16.29% 15,138.86
2023 21,656.44 Est @ 12.43% 15,707.38
2024 23,763.58 Est @ 9.73% 15,905.87
2025 25,626.62 Est @ 7.84% 15,829.46
2026 27,296.69 Est @ 6.52% 15,560.15
2027 28,822.80 Est @ 5.59% 15,162.45
2028 30,247.40 Est @ 4.94% 14,684.20
2029 31,605.15 Est @ 4.49% 14,159.54
Present value of next 10 years cash flows ₩148,805.00
KOSDAQ:A053030 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= ₩31,605.15 × (1 + 3.43%) ÷ (8.36% – 3.43%)
₩663,004.50
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= ₩663,004.50 ÷ (1 + 8.36%)10
₩297,035.18
KOSDAQ:A053030 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= ₩148,805.00 + ₩297,035.18
₩445,840.18
Equity Value per Share
(KRW)
= Total value / Shares Outstanding
= ₩445,840.18 / 31.19
₩14295.33
KOSDAQ:A053030 Discount to Share Price
Calculation Result
Value per share (KRW) From above. ₩14,295.33
Current discount Discount to share price of ₩10,600.00
= -1 x (₩10,600.00 - ₩14,295.33) / ₩14,295.33
25.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price BINEX is available for.
Intrinsic value
26%
Share price is ₩10600 vs Future cash flow value of ₩14295.33
Current Discount Checks
For BINEX to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • BINEX's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • BINEX's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for BINEX's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are BINEX's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
KOSDAQ:A053030 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in KRW ₩273.00
KOSDAQ:A053030 Share Price ** KOSDAQ (2020-04-03) in KRW ₩10600
Korea (Republic of) Pharmaceuticals Industry PE Ratio Median Figure of 53 Publicly-Listed Pharmaceuticals Companies 23.75x
Korea (Republic of) Market PE Ratio Median Figure of 1,311 Publicly-Listed Companies 12.31x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of BINEX.

KOSDAQ:A053030 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= KOSDAQ:A053030 Share Price ÷ EPS (both in KRW)

= 10600 ÷ 273.00

38.83x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BINEX is overvalued based on earnings compared to the KR Pharmaceuticals industry average.
  • BINEX is overvalued based on earnings compared to the Korea (Republic of) market.
Price based on expected Growth
Does BINEX's expected growth come at a high price?
Raw Data
KOSDAQ:A053030 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 38.83x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
Korea (Republic of) Pharmaceuticals Industry PEG Ratio Median Figure of 10 Publicly-Listed Pharmaceuticals Companies 0.98x
Korea (Republic of) Market PEG Ratio Median Figure of 356 Publicly-Listed Companies 0.71x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for BINEX, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on BINEX's assets?
Raw Data
KOSDAQ:A053030 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in KRW ₩5,169.74
KOSDAQ:A053030 Share Price * KOSDAQ (2020-04-03) in KRW ₩10600
Korea (Republic of) Pharmaceuticals Industry PB Ratio Median Figure of 77 Publicly-Listed Pharmaceuticals Companies 1.71x
Korea (Republic of) Market PB Ratio Median Figure of 1,954 Publicly-Listed Companies 0.84x
KOSDAQ:A053030 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= KOSDAQ:A053030 Share Price ÷ Book Value per Share (both in KRW)

= 10600 ÷ 5,169.74

2.05x

* Primary Listing of BINEX.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BINEX is overvalued based on assets compared to the KR Pharmaceuticals industry average.
X
Value checks
We assess BINEX's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. BINEX has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

A053030 Future Performance

 How is BINEX expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
21.6%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is BINEX expected to grow at an attractive rate?
  • Unable to compare BINEX's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare BINEX's earnings growth to the Korea (Republic of) market average as no estimate data is available.
  • Unable to compare BINEX's revenue growth to the Korea (Republic of) market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
KOSDAQ:A053030 Future Growth Rates Data Sources
Data Point Source Value (per year)
Korea (Republic of) Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 21.6%
Korea (Republic of) Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 10.7%
Korea (Republic of) Market Earnings Growth Rate Market Cap Weighted Average 27.8%
Korea (Republic of) Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
KOSDAQ:A053030 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in KRW Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
KOSDAQ:A053030 Future Estimates Data
Date (Data in KRW Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 136,600 13,900 10,600 1
2020-04-04
KOSDAQ:A053030 Past Financials Data
Date (Data in KRW Millions) Revenue Cash Flow Net Income *
2019-12-31 125,259 10,785 8,504
2019-09-30 122,942 19,557 13,092
2019-06-30 119,099 16,314 13,565
2019-03-31 111,203 17,211 8,878
2018-12-31 104,043 13,561 6,337
2018-09-30 91,167 5,127 -4,232
2018-06-30 84,136 7,163 -9,325
2018-03-31 79,031 3,341 -12,419
2017-12-31 78,026 8,136 -10,797
2017-06-30 80,782 13,053 -7,528
2017-03-31 81,500 10,766 -3,065

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if BINEX is high growth as no earnings estimate data is available.
  • Unable to determine if BINEX is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
KOSDAQ:A053030 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from BINEX Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

KOSDAQ:A053030 Future Estimates Data
Date (Data in KRW Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31 335.00 335.00 335.00 1.00
2020-04-04
KOSDAQ:A053030 Past Financials Data
Date (Data in KRW Millions) EPS *
2019-12-31 273.00
2019-09-30 419.84
2019-06-30 435.04
2019-03-31 284.55
2018-12-31 203.00
2018-09-30 -130.33
2018-06-30 -287.92
2018-03-31 -392.53
2017-12-31 -341.28
2017-06-30 -252.89
2017-03-31 -100.10

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if BINEX will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess BINEX's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Korea (Republic of) market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Korea (Republic of) market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
BINEX has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

A053030 Past Performance

  How has BINEX performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare BINEX's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • BINEX has delivered over 20% year on year earnings growth in the past 5 years.
  • BINEX's 1-year earnings growth is less than its 5-year average (34.2% vs 63.1%)
  • BINEX's earnings growth has exceeded the KR Pharmaceuticals industry average in the past year (34.2% vs 19.4%).
Earnings and Revenue History
BINEX's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from BINEX Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

KOSDAQ:A053030 Past Revenue, Cash Flow and Net Income Data
Date (Data in KRW Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 125,258.58 8,504.13 43,179.24 1,035.10
2019-09-30 122,942.26 13,092.43 40,635.00 1,008.79
2019-06-30 119,099.08 13,565.38 40,408.26 999.55
2019-03-31 111,203.09 8,878.32 40,394.50 945.18
2018-12-31 104,043.18 6,337.27 39,297.34 894.57
2018-09-30 91,167.43 -4,231.94 40,651.23 784.75
2018-06-30 84,136.03 -9,324.87 39,074.14 658.39
2018-03-31 79,030.51 -12,418.55 35,550.51 659.82
2017-12-31 78,026.38 -10,797.49 34,419.38 622.05
2017-06-30 80,781.70 -7,528.03 30,512.25 704.41
2017-03-31 81,500.20 -3,065.01 29,822.83 760.52
2016-12-31 80,924.37 -3,143.81 29,053.40 817.80
2016-09-30 77,575.99 -12,168.66 29,469.25 885.12
2016-06-30 74,889.65 -10,196.49 27,535.48 955.92
2016-03-31 71,804.37 -9,552.72 26,416.89 1,043.12
2015-12-31 66,539.33 -9,289.10 24,323.55 1,168.60
2014-09-30 56,724.14 -2,357.31 21,230.76 1,404.30
2014-06-30 58,746.25 -3,157.91 21,328.10 1,682.45
2014-03-31 59,259.81 -3,099.24 20,956.20 1,877.41
2013-12-31 57,296.77 -4,069.08 20,833.70 2,181.02
2013-09-30 60,440.18 -6,532.58 19,130.19 1,867.32
2013-06-30 55,405.58 -7,881.22 20,649.34 1,404.78

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • BINEX has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • BINEX used its assets more efficiently than the KR Pharmaceuticals industry average last year based on Return on Assets.
  • BINEX has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess BINEX's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
BINEX has a total score of 4/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

A053030 Health

 How is BINEX's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up BINEX's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • BINEX is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • BINEX's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of BINEX's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 3.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from BINEX Company Filings, last reported 3 months ago.

KOSDAQ:A053030 Past Debt and Equity Data
Date (Data in KRW Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 161,379.42 23,158.85 24,510.35
2019-09-30 156,905.99 22,694.83 23,683.31
2019-06-30 155,227.76 22,241.72 22,684.01
2019-03-31 153,579.59 21,811.66 23,567.62
2018-12-31 152,268.37 24,386.69 20,675.52
2018-09-30 137,836.77 23,962.33 14,574.47
2018-06-30 135,928.48 23,552.39 15,976.38
2018-03-31 137,354.57 26,157.59 17,439.75
2017-12-31 131,726.60 25,770.37 19,790.30
2017-06-30 137,185.69 28,740.17 13,104.05
2017-03-31 142,433.30 28,030.44 14,281.82
2016-12-31 141,774.88 26,647.60 7,284.84
2016-09-30 148,371.01 23,945.27 11,689.01
2016-06-30 148,579.69 25,604.92 10,199.66
2016-03-31 150,567.51 25,277.14 15,262.30
2015-12-31 144,144.40 23,954.22 13,895.52
2014-09-30 105,589.08 19,653.10 14,744.16
2014-06-30 105,352.48 21,821.80 13,704.65
2014-03-31 99,200.60 17,190.50 10,549.47
2013-12-31 97,446.93 16,560.00 14,638.25
2013-09-30 91,776.29 22,310.00 9,916.62
2013-06-30 91,603.30 22,080.00 13,159.32
  • BINEX's level of debt (14.4%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (18.1% vs 14.4% today).
  • Debt is well covered by operating cash flow (46.6%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 6.5x coverage).
X
Financial health checks
We assess BINEX's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. BINEX has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

A053030 Dividends

 What is BINEX's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from BINEX dividends.
If you bought ₩2,000 of BINEX shares you are expected to receive ₩0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate BINEX's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate BINEX's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
KOSDAQ:A053030 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Korea (Republic of) Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 40 Stocks 0.9%
Korea (Republic of) Market Average Dividend Yield Market Cap Weighted Average of 908 Stocks 2.9%
Korea (Republic of) Minimum Threshold Dividend Yield 10th Percentile 0.6%
Korea (Republic of) Bottom 25% Dividend Yield 25th Percentile 1.2%
Korea (Republic of) Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

KOSDAQ:A053030 Future Dividends Estimate Data
Date (Data in ₩) Dividend per Share (annual) Avg. No. Analysts
2020-12-31
2020-04-04
KOSDAQ:A053030 Past Annualized Dividends Data
Date (Data in ₩) Dividend per share (annual) Avg. Yield (%)
2011-03-10 0.000 0.000
2010-11-12 0.000 0.000
2010-08-16 0.000 0.000
2010-05-17 0.000 0.000
2010-03-31 0.000 0.000
2009-11-16 50.000 0.636
2009-08-05 50.000 0.472
2009-08-04 50.000 0.489
2009-05-15 50.000 0.823
2009-04-08 50.000 1.117

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as BINEX has not reported any payouts.
  • Unable to verify if BINEX's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of BINEX's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as BINEX has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess BINEX's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.6%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can BINEX afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. BINEX has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

A053030 Management

 What is the CEO of BINEX's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jung-Tak Moon
AGE 53
CEO Bio

Jung-Tak Moon serves as the Chief Executive Officer of Binex Company Ltd. Jung-Tak Moon served as a Director of Genexin Corporation.

CEO Compensation
  • Insufficient data for Jung-Tak to compare compensation growth.
  • Insufficient data for Jung-Tak to establish whether their remuneration is reasonable compared to companies of similar size in .
Management Team

Won-Seok Kim

TITLE
Head of Production Division and Director
AGE
56

Young-Cheol Son

TITLE
Head of Management Support Division and Director
AGE
55

Jung-Jin Lee

TITLE
Head of Bio-Tech Research Center and Director
AGE
55

Byung-In Lee

TITLE
Head of Business Operation Division and Director
AGE
54

Jung-Won Seo

TITLE
Head of Bio Processing Division and Director
AGE
57

Myung-Cheol Lee

TITLE
Managing Director
AGE
61

Soo-Yong Jin

TITLE
Managing Director
AGE
51

Hyuk-Jong Lee

TITLE
Managing Director
AGE
50

Doo-Hyun Kim

TITLE
Vice President
AGE
67

Jung-Tak Moon

TITLE
Chief Executive Officer
AGE
53
Board of Directors

Baek-Cheon Lee

TITLE
Chairman
AGE
77

Won-Seok Kim

TITLE
Head of Production Division and Director
AGE
56

Young-Cheol Son

TITLE
Head of Management Support Division and Director
AGE
55

Jung-Jin Lee

TITLE
Head of Bio-Tech Research Center and Director
AGE
55

Byung-In Lee

TITLE
Head of Business Operation Division and Director
AGE
54

Jung-Won Seo

TITLE
Head of Bio Processing Division and Director
AGE
57

Myung-Ho Jeon

TITLE
Director
AGE
47

Woo-Jib Kim

TITLE
Director
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (₩) Value (₩)
X
Management checks
We assess BINEX's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. BINEX has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

A053030 News

Simply Wall St News

A053030 Company Info

Description

BINEX Co., Ltd. operates as a pharmaceutical company in South Korea. It offers bisroot products; GI tract and antispasmodic, and antiulcer agents; NSAIDs; cardiovascular and urology products; hepatic protectors; ointments and creams; ophthalmic solutions; CNS agents; digestive products; conspitation and blood circulation products; antibiotic and antifungal agents; cough and cold remedy products; vitamins and nutrients; antihistamine products; antivertigo products; and OTC products. BINEX Co., Ltd. has a co-development partnership with Genexine, Inc. to develop COVID-19 vaccine. The company was founded in 1957 and is based in Incheon, South Korea.

Details
Name: BINEX Co., Ltd.
A053030
Exchange: KOSDAQ
Founded: 1957
₩330,590,913,200
31,187,822
Website: http://www.bi-nex.co.kr
Address: BINEX Co., Ltd.
7-48 SongDo-Dong,
YeonSu-Gu,
Incheon,
406-840,
South Korea
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
KOSDAQ A053030 Common Stock KOSDAQ KR KRW 07. Aug 2001
Number of employees
Current staff
Staff numbers
0
BINEX employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/04 18:00
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/03/24
Last earnings filing: 2020/03/13
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.